Ceftazidime-avibactam in ceftazidime-resistant infections.
Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel. Electronic address: yehudac@tlvmc.gov.il.
Yehuda
Y
Carmeli
AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
Jon
J
Armstrong
AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
Paul
P
Newell
AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA.
Greg
G
Stone
AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, Macclesfield, UK.
Angela
A
Wardman
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D002442:Ceftazidime; D004338:Drug Combinations; D006801:Humans; D008826:Microbial Sensitivity Tests; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D065093:beta-Lactamase Inhibitors; D002442:Ceftazidime